Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iBioIBIO -1.04%30 OCF Yield % is -30.41 as of Jul. 15, 2026. GuruFocus rates IBIO with a GF Score™ of 30/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, iBio ranks worse than 75.82% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for iBio's OCF Yield % or its related term are showing as below:
IBIO'
s OCF Yield % Range Over the Past 10 Years
Min: -1411.72 Med: -65.82 Max: -1.73
Current: -30.41
During the past 13 years, the highest OCF Yield % of iBio was -1.73%. The lowest was -1411.72%. And the median was -65.82%.
IBIO's OCF Yield % is ranked worse than 75.82% of 1410
companies
in the Biotechnology industry
Industry Median: -8.295
vs IBIO: -30.41
iBio's OCF Margin % for the quarter that ended in Mar. 2026 was %.
iBio OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
iBio OCF Yield % Related Terms
iBio OCF Yield % Historical Data
* Premium members only.
The historical data trend for iBio's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, iBio's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iBio OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, iBio's OCF Yield % distribution charts can be found below:
* The bar in red indicates where iBio's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iBio (IBIO) has a OCF Yield % of -30.41 as of Jul. 15, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on iBio and its competitors. According to the industry distribution chart, iBio ranks #1069 out of 1410 companies in the Biotechnology industry, placing it in the top 75.8%.
Is iBio's OCF Yield % too high?
iBio's current OCF Yield % is -30.41. Based on the distribution chart, iBio ranks #1069 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, iBio has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iBio's OCF Yield % compare to RNTX and RANI?
According to the Biotechnology industry distribution chart, iBio ranks #1069 out of 1410 companies for OCF Yield %. This places iBio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on iBio and its competitors. iBio's current OCF Yield % is -30.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iBio stock overvalued right now?
Based on GuruFocus' analysis, iBio (IBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $1.44 — trading 2770% above its estimated fair value. The current OCF Yield % is -30.41. iBio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For iBio (IBIO), the current OCF Yield % is -30.41 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iBio (IBIO) Overvalued in 2026?
Based on GuruFocus' analysis, iBio stock appears to be overvalued.
The current stock price of $1.44 is trading 2770% above its estimated GF Value™ of $0.05.
GuruFocus considers iBio to be Significantly Overvalued.
Key valuation signals for IBIO:
OCF Yield %: -30.41
GF Value™: $0.05 vs. price of $1.44 (2770% above fair value)
No single metric tells the full story. See the IBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
30GF Score
Get the complete analysis for IBIO
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBIO has been successfully added to your 
